Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Perform rating on Biomarin Pharmaceutical (BMRN) and raises the price target from $83 to $85.

April 25, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has maintained a Sector Perform rating on Biomarin Pharmaceutical and increased the price target from $83 to $85.
The increase in price target by Scotiabank reflects a positive outlook on Biomarin Pharmaceutical's stock, likely due to anticipated performance or favorable market conditions. This adjustment suggests confidence in the company's future prospects, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 90